Multiple sclerosis cost-effectiveness of therapy

Jump to navigation Jump to search

Multiple sclerosis Microchapters


Patient Information


Historical Perspective




Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography or Ultrasound

CT Scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis cost-effectiveness of therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Multiple sclerosis cost-effectiveness of therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis cost-effectiveness of therapy

CDC on Multiple sclerosis cost-effectiveness of therapy

Multiple sclerosis cost-effectiveness of therapy in the news

Blogs on Multiple sclerosis cost-effectiveness of therapy

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.


Given the morbidity and mortality associated with multiple sclerosis, as well as the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective. Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar. Controlling acute attack can reduce the economic burden of MS disease.

Cost effectiveness


  1. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (September 2009). "Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis". J Manag Care Pharm. 15 (7): 543–55. doi:10.18553/jmcp.2009.15.7.543. PMID 19739877.
  2. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (October 1998). "A comprehensive assessment of the cost of multiple sclerosis in the United States". Mult. Scler. 4 (5): 419–25. doi:10.1177/135245859800400504. PMID 9839302.
  3. Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT (April 2005). "Cost of multiple sclerosis by level of disability: a review of literature". Mult. Scler. 11 (2): 232–9. doi:10.1191/1352458505ms1137oa. PMID 15794399.

Template:WH Template:WS